Publication at Faculty of Medicine in Hradec Králové |
2014
Abstract
Incretin glucagon like peptid -1 receptor agonists are also known as incretin mimetics. These are the new drugs for the teatment of type 2 diabetes, which have a significant antihyperglycemic effect.
For the individual treatment can be used short - acting and long - acting drugs. In addition to glucose effect there are influenced another factors, especially weight and hypertension.
The patophysiological mechanism of their action, pharmacological and clinical differences and their use in clinical prectice are described.